June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Results of a Phase 3, Randomized, Double-Masked, Vehicle Controlled Study
(Phase 3c) Evaluating the Safety and Efficacy of DEXTENZATM (dexamethasone insert) 0.4 mg for the Treatment of Ocular Inflammation and Pain after Cataract Surgery
Author Affiliations & Notes
  • Jonathan H Talamo
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Sydney L Tyson
    SurgiCenter of Vineland, Vineland, New Jersey, United States
  • Shamik Bafna
    Cleveland Eye Clinic, Elyria, Ohio, United States
  • Gira P Joseph
    Ophthalmology Consultants, St. Louis, Missouri, United States
  • Damien F Goldberg
    Wolstan & Goldberg Eye Associates, Torrance, California, United States
  • Jason J Jones
    Jones Eye Clinic, Sioux City, Iowa, United States
  • Michael P Jones
    Quantum Vision Centers, Belleville, Illinois, United States
  • Janet K Kim
    Hull Eye and Surgery Center, Lancaster, California, United States
  • James B Martel
    Martel Eye Medical Group, Rancho Cordova, California, United States
  • Michael L Nordlund
    Cincinnati Eye Institute, Cincinnati, Ohio, United States
  • Ian K Piovanetti
    Centro Oftalmico Metropolitano, San Juan, Puerto Rico, United States
  • Inder Paul Singh
    The Eye Centers of Racine & Kenosha, Racine, Wisconsin, United States
  • Jamie Lynne Metzinger
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Deepa Mulani
    Ocular Therapeutix, Bedford, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Jonathan Talamo, Ocular Therapeutix (E); Sydney Tyson, Ocular Therapeutix (F); Shamik Bafna, Ocular Therapeutix (F); Gira Joseph, Ocular Therapeutix (F); Damien Goldberg, Ocular Therapeutix (F); Jason Jones, Ocular Therapeutix (F); Michael Jones, Ocular Therapeutix (F); Janet Kim, Ocular Therapeutix (F); James Martel, Ocular Therapeutix (F); Michael Nordlund, Ocular Therapeutix (F); Ian Piovanetti, Ocular Therapeutix (F); Inder Paul Singh, Ocular Therapeutix (F); Jamie Lynne Metzinger, Ocular Therapeutix (E); Deepa Mulani, Ocular Therapeutix (E)
  • Footnotes
    Support  Ocular Therapeutix supported this research.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1825. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jonathan H Talamo, Sydney L Tyson, Shamik Bafna, Gira P Joseph, Damien F Goldberg, Jason J Jones, Michael P Jones, Janet K Kim, James B Martel, Michael L Nordlund, Ian K Piovanetti, Inder Paul Singh, Jamie Lynne Metzinger, Deepa Mulani; Results of a Phase 3, Randomized, Double-Masked, Vehicle Controlled Study
      (Phase 3c) Evaluating the Safety and Efficacy of DEXTENZATM (dexamethasone insert) 0.4 mg for the Treatment of Ocular Inflammation and Pain after Cataract Surgery. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1825.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the safety and efficacy of DEXTENZA, an extended release dexamethasone insert, when placed in the canaliculus of the eye for the treatment of post-surgical inflammation and pain in subjects who have undergone cataract extraction with intraocular lens implantation.

Methods : This was a prospective, multicenter, randomized, parallel-arm, double-masked, vehicle controlled study. Subjects enrolled in the study were randomized (1:1) on Day 1 to receive either DEXTENZA or placebo vehicle insert (PV); the test article was inserted into the inferior vertical canaliculus of the operated eye intraoperatively, within minutes of the completion of cataract surgery. Subjects completed follow-up visits at post-operative Days 2, 4, 8, 14, 30 and 45. The primary endpoints evaluated were the absence of anterior chamber (AC) cells (score of 0) at Day 14 and the absence of pain (score of 0) at Day 8. Safety evaluations included adverse event (AE) collection, and ocular examination findings, including slit lamp, dilated fundus, visual acuity, and intraocular pressure exams.

Results : A total of 438 subjects were randomized into the study. Baseline demographics were similar across both cohorts. DEXTENZA met both primary efficacy endpoints, showing statistical superiority over PV; 52.3% of subjects receiving DEXTENZA had no AC cells at Day 14, compared to 31.1% of subjects receiving PV (p<0.0001), and 79.6% of subjects receiving DEXTENZA had no pain at Day 8, compared to 61.3% of PV subjects (p<0.0001). Statistical superiority of DEXTENZA over PV was observed as early as Day 2 for absence of ocular pain and Day 4 for absence of AC cells. Ocular AEs observed in >5% of subjects were limited to eye inflammation and increased intraocular pressure. There were no treatment-related serious AEs. No subjects experienced a treatment-emergent AE leading to subject withdrawal.

Conclusions : DEXTENZA was shown to be statistically superior to PV in treating post-surgical inflammation and pain in subjects having undergone cataract extraction; superiority over PV was observed as early as Day 2 for absence of ocular pain and Day 4 for absence of cells. Treatment with DEXTENZA was safe and well-tolerated.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

Summary of the Co-Primary Efficacy Endpoint Results

Summary of the Co-Primary Efficacy Endpoint Results

 

Summary of Adverse Events

Summary of Adverse Events

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×